May 1, 2018 / 1:00 PM / 5 months ago

BRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound

May 1 (Reuters) - Arena Pharmaceuticals Inc:

* ARENA PHARMACEUTICALS AND OUTPOST MEDICINE ENTER INTO LICENSING AGREEMENT FOR UNDISCLOSED NOVEL COMPOUND

* ARENA PHARMACEUTICALS - WILL GET UPFRONT FEE COMPRISED OF CASH AND EQUITY TOTALING $3.0 MILLION

* ARENA PHARMACEUTICALS - ELIGIBLE TO GET ABOUT $100 MILLION IN MILESTONE PAYMENTS AS PART OF DEAL

* ARENA - CO, OUTPOST MEDICINE TO ADVANCE UNDISCLOSED, PRECLINICAL COMPOUND WITH POTENTIAL UTILITY IN TREATING GENITOURINARY DISORDERS

* ARENA - COMPOUND THAT IS PART OF DEAL WITH OUTPOST MEDICINE TARGETS UNDISCLOSED G PROTEIN-COUPLED RECEPTOR , WAS INTERNALLY DISCOVERED BY ARENA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below